Lilly and AstraZeneca to Develop Second Potentially Disease-Modifying Treatment for Alzheimer's Disease
The build-up of plaques in the brain containing the peptide amyloid-beta (Aβ) is one of the characteristics of AD. MEDI1814 binds selectively to Aβ42, a form of Aβ which is particularly associated with the disease. Binding dose-dependently reduces levels of this peptide, potentially slowing the progression of AD.
"At Lilly, we recognize the significant burden Alzheimer's disease places on patients, caregivers and our society, and we remain committed to finding ways to change the course of the disease," said
"We are excited to build on an already productive collaboration with Lilly, which combines the expertise of our two companies, with a new program focused on the amyloid-beta pathway," said
Under the terms of the new agreement, Lilly will make a
About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and newsroom.lilly.com/social-channels.
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about the benefits of Lilly's worldwide agreement to co-develop and commercialize MEDI1814 with AstraZeneca. It reflects Lilly's current belief, however, as with any such undertaking, there are substantial risks and uncertainties in implementing the transaction and in drug development. Among other things, there can be no guarantee that Lilly will realize the expected benefits of the transaction, that the molecule will be approved on the anticipated timeline or at all, or that the potential product will be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's most recent Form 10-K and Form
10-Q filings with the
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/lilly-and-astrazeneca-to-develop-second-potentially-disease-modifying-treatment-for-alzheimers-disease-300375924.html
News Provided by Acquire Media